REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Dec 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-12-12

Reporting Person: YANCOPOULOS GEORGE (Director, President & CSO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-13	Common Stock	M	195438	$21.92	Acquired	786786	Direct
2017-12-13	Common Stock	F	11124	$385.08	Disposed	775662	Direct
2017-12-13	Common Stock	F	95050	$385.08	Disposed	680612	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-13	Non-Qualified Stock Option (right to buy)	$21.92	M	195438	Disposed	2017-12-17	Common Stock (195438)	Direct
2017-12-12	Non-Qualified Stock Option (right to buy)	$378.98	A	139474	Acquired	2027-12-12	Common Stock (139474)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	323777	Indirect
Common Stock	176223	Indirect
Common Stock	5702	Indirect
Common Stock	64058	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F3: The stock option award vests in four equal annual installments, commencing one year after the date of grant.